Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.

source https://finance.yahoo.com/news/roche-reports-positive-data-tecentriq-084708105.html?.tsrc=rss